Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations

Simply Wall St

May 10, 2025

Avidity Biosciences (NASDAQ:RNA) First Quarter 2025 Results

Key Financial Results

Net loss: US$115.8m (loss widened by 68% from 1Q 2024).
US$0.90 loss per share (further deteriorated from US$0.79 loss in 1Q 2024).

Our free stock report includes 2 warning signs investors should be aware of before investing in Avidity Biosciences. Read for free now.

earnings-and-revenue-history — NasdaqGM:RNA Earnings and Revenue History May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Avidity Biosciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 40%. Earnings per share (EPS) also missed analyst estimates by 6.3%.

Looking ahead, revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 13% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Avidity Biosciences, and understanding them should be part of your investment process.

If you're looking to trade Avidity Biosciences, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.